Vascular Solutions 10-Q 2006 Q2 Quarterly report

UNITED STATES
SECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2006

OR

o    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to ________

Commission File Number: 0-27605

VASCULAR SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)

Minnesota	41-1859679
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

6464 Sycamore Court
Minneapolis, Minnesota 55369
(Address of principal executive offices, including zip code)

(763) 656-4300
(Registrant’s telephone number, including area code)

Not Applicable
(Former name, former address and former
fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes xNoo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act
Large accelerated filer  oAccelerated filerxNon-accelerated filero

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes oNox

The registrant had 15,030,009 shares of common stock, $.01 par value per share, outstanding as of July 21, 2006.

VASCULAR SOLUTIONS, INC.

TABLE OF CONTENTS

		Page
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)
	Consolidated Balance Sheets	2
	Consolidated Statements of Operations	3
	Consolidated Statements of Cash Flows	4
	Notes to Unaudited Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21
Item 4.	Controls and Procedures	21
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	22
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Submission of Matters to a Vote of Security Holders	23
Item 5.	Other Information	23
Item 6.	Exhibits	24

1

PART 1. FINANCIAL INFORMATION

Item 1. Financial Statements

VASCULAR SOLUTIONS, INC.

Consolidated Balance Sheets

	June 30,			December 31,
	2006			2005
	(unaudited)			(see note)
Assets
Current assets:
Cash and cash equivalents	$	2,226,000		$	4,282,000
Accounts receivable, net of reserves of $190,000 and $140,000 in 2006 and 2005, respectively		6,100,000			4,854,000
Inventories		8,045,000			6,962,000
Prepaid expenses		536,000			578,000
Total current assets		16,907,000			16,676,000
Property and equipment, net		3,273,000			2,955,000
Intangible assets, net		193,000			265,000
Total assets	$	20,373,000		$	19,896,000
Liabilities and shareholders’ equity
Current liabilities:
Current portion of long-term debt	$	733,000		$	—
Accounts payable		1,642,000			2,898,000
Accrued compensation		1,694,000			1,196,000
Accrued expenses		1,258,000			1,695,000
Total current liabilities		5,327,000			5,789,000
Long-term debt, net of current portion		1,267,000			—
Shareholders’ equity:
Common stock, $0.01 par value: Authorized shares – 40,000,000 Issued and outstanding shares – 15,030,869 – 2006; 14,642,225 – 2005		150,000			147,000
Additional paid-in capital		79,010,000			77,793,000
Other		(82,000	)		(42,000	)
Accumulated deficit		(65,299,000	)		(63,791,000	)
Total shareholders’ equity		13,779,000			14,107,000
Total liabilities and shareholders’ equity	$	20,373,000		$	19,896,000

See accompanying notes.

Note: The consolidated balance sheet at December 31, 2005 has been derived from the audited financial statements at that date.

2

VASCULAR SOLUTIONS, INC.

Consolidated Statements of Operations

	Three Months Ended June 30,					Six Months Ended June 30,
	2006			2005		2006			2005
	(unaudited)					(unaudited)
Net sales	$	10,911,000		$	8,079,000	$	20,863,000		$	15,353,000
Cost of goods sold (1)		3,647,000			2,308,000		6,847,000			4,366,000
Gross profit		7,264,000			5,771,000		14,016,000			10,987,000
Operating expenses:
Research and development (1)		1,026,000			965,000		2,024,000			1,844,000
Clinical and regulatory (1)		618,000			536,000		1,200,000			977,000
Sales and marketing (1)		4,276,000			3,380,000		8,675,000			6,470,000
General and administrative (1)		1,001,000			664,000		1,888,000			1,250,000
Thrombin qualification		952,000			139,000		1,621,000			626,000
Amortization of purchased technology		18,000			54,000		73,000			109,000
Total operating expenses		7,891,000			5,738,000		15,481,000			11,276,000
Operating income (loss)		(627,000	)		33,000		(1,465,000	)		(289,000	)
Other income (expenses)
Interest expense		(54,000	)		—		(102,000	)		—
Interest income		28,000			42,000		59,000			75,000
Net income (loss)	$	(653,000	)	$	75,000	$	(1,508,000	)	$	(214,000	)
Net income (loss) per share – basic	$	(0.04	)	$	0.01	$	(0.10	)	$	(0.01	)
Net income (loss) per share – diluted	$	(0.04	)	$	0.00	$	(0.10	)	$	(0.01	)
(1) Includes stock-based compensation charges of:
Cost of goods sold		31,000			—		69,000			—
Research and development		50,000			—		100,000			—
Clinical and regulatory		22,000			—		49,000			—
Sales and marketing		101,000			—		232,000			—
General and administrative		112,000			—		179,000			—
		316,000			—		629,000			—

See accompanying notes.

3

VASCULAR SOLUTIONS, INC.

Consolidated Statements of Cash Flows

	Six Months Ended June 30,
	2006			2005
		(unaudited)
Operating activities
Net loss	$	(1,508,000	)	$	(214,000	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		454,000			255,000
Amortization		73,000			109,000
Stock-based compensation		629,000			—
Deferred compensation expense		15,000			11,000
Change in allowance for doubtful accounts		50,000			(20,000	)
Changes in operating assets and liabilities:
Accounts receivable		(1,287,000	)		(747,000	)
Inventories		(1,075,000	)		(92,000	)
Prepaid expenses		44,000			55,000
Accounts payable		(1,257,000	)		12,000
Accrued compensation and expenses		(40,000	)		190,000
Net cash used in operating activities		(3,902,000	)		(441,000	)
Investing activities
Purchase of property and equipment		(797,000	)		(368,000	)
Proceeds received on disposition of property and equipment		26,000			—
Net cash used in investing activities		(771,000	)		(368,000	)
Financing activities
Proceeds from borrowings on long-term debt		2,000,000			—
Proceeds from the exercise of stock options, stock warrants and sale of stock, net of expenses		580,000			802,000
Net cash provided by financing activities		2,580,000			802,000
Effect of exchange rate changes on cash and cash equivalents		37,000			(130,000	)
(Decrease) in cash and cash equivalents		(2,056,000	)		(137,000	)
Cash and cash equivalents at beginning of period		4,282,000			7,184,000
Cash and cash equivalents at end of period	$	2,226,000		$	7,047,000
Supplemental disclosure of cash flow
Cash paid for interest	$	86,000		$	—

See accompanying notes.

4

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements

(1) Basis of Presentation

The accompanying unaudited financial statements of Vascular Solutions, Inc. (the Company) have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal, recurring adjustments considered necessary for a fair presentation have been included. The financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2005 included in the Annual Report on Form 10-K of the Company filed with the Securities and Exchange Commission. Interim results of operations are not necessarily indicative of the results to be expected for the full year or any other interim periods.

(2) Stock-Based Compensation

The Company has various types of stock-based compensation plans. These plans are administered by the compensation committee of the Board of Directors, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the award. Readers should refer to Notes 9 and 10 of the Company’s consolidated financial statements in the Annual Report on Form 10-K for the fiscal year ended December 31, 2005, for additional information related to these stock-based compensation plans.

Effective January 1, 2006, the Company adopted Statement No. 123R, Share-Based Payment (SFAS 123R), which requires companies to measure and recognize compensation expense for all stock-based payments at fair value. SFAS 123R is being applied on the modified prospective basis. Prior to the adoption of SFAS 123R, the Company accounted for its stock-based compensation plans under the recognition and measurement principles of Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations, and accordingly, recognized no compensation expense related to the stock-based plans.

Under the modified prospective approach, SFAS 123R applies to new awards and to awards that were outstanding on January 1, 2006 that are subsequently modified, repurchased, cancelled or vest. Under the modified prospective approach, compensation cost recognized for the first and second quarters of fiscal 2006 includes compensation cost for all share-based payments granted prior to, but not yet vested on, January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of SFAS 123R, and compensation cost for all shared-based payments granted subsequent to January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of SFAS 123R. Prior periods were not restated to reflect the impact of adopting the new standard.

5

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements-Continued

As a result of adopting SFAS 123R on January 1, 2006, the net loss and net loss per share for the three months ended June 30, 2006, were $316,000 and $0.02 lower, respectively, than if the Company had continued to account for stock-based compensation under APB Opinion No. 25. The net loss and net loss per share for the six months ended June 30, 2006, were $629,000 and $0.04 lower, respectively, than if the Company had continued to account for stock-based compensation under APB Opinion No. 25.

The following table illustrates the effect on net loss and net loss per share had the Company accounted for stock-based compensation in accordance with SFAS 123R for the three and six months ended June 30, 2005:

	Three Months Ended June 30, 2005 (unaudited)			Six Months Ended June 30, 2005 (unaudited)
Net income (loss), as reported	$	75,000		$	(214,000	)
Deduct: Total stock-based employee and director compensation expense determined under fair-value-based method for all awards		(603,000	)		(881,000	)
Pro forma net loss	$	(528,000	)	$	(1,095,000	)
Net income (loss) per share:
Basic income (loss) – as reported	$	0.01		$	(0.01	)
Basic loss – pro forma	$	(0.04	)	$	(0.08	)
Diluted income (loss) – as reported	$	0.00		$	(0.01	)
Diluted loss – pro forma	$	(0.04	)	$	(0.08	)

The Company uses the Black-Scholes option-pricing model to estimate fair value of stock-based awards with the following weighted average assumptions:

	June 30, 2006	June 30, 2005
Stock Options and Awards:
Expected life (years)	5.50	5.50
Expected volatility	55%	61%
Dividend yield	0%	0%
Risk-free interest rate	4.77%	4.07%
Employee Stock Purchase Plan:
Expected life (years)	2.00	2.00
Expected volatility	42%	61%
Dividend yield	0%	0%
Risk-free interest rate	4.80%	3.64%

6

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements-Continued

The Company calculates expected volatility for stock options and awards using historical volatility. The starting point for the historical period used is based on a material change in the Company’s operations that occurred in the third quarter of 2003. The Company estimates the forfeiture rate for stock options using 10% for key employees and 15% for non-key employees.

The Company calculates expected volatility for employee stock purchase plan shares using historical volatility over a two year period. A two year period is used to coincide with the maximum two year offering period under the employee stock purchase plan.

The Company has a stock option and stock award plan (the Stock Option Plan) which provides for the granting of stock options, restricted shares and alternative stock appreciation rights to employees, directors and consultants. Incentive stock options may be granted only to employees of the Company. Options which do not qualify as incentive stock options and awards of restricted shares may be granted to both employees and to non-employee directors and consultants. Under the Stock Option Plan, stock options must be granted at an exercise price not less than the fair market value of the Company’s common stock on the grant date. Prior to the initial public offering in July 2000, the Board of Directors determined the fair value of the Company’s common shares underlying options by assessing the business progress of the Company as well as the market conditions for medical device companies and other external factors. The options expire on the date determined by the Board of Directors but may not extend more than ten years from the grant date. The incentive stock options generally become exercisable over a four-year period and the nonqualified stock options generally become exercisable over a two-year period. Unexercised options are canceled 90 days after termination, and unvested awards are canceled on the date of termination of employment and become available under the Stock Option Plan for future grants.

The holder of a restricted share award is generally entitled at all times on and after the date of issuance of the restricted shares to exercise the rights of a shareholder of the Company, including the right to vote the shares and the right to receive dividends on the shares. On January 24, 2006, the Company granted restricted shares to employees under the Stock Option Plan. The restricted shares vest over a four-year period based on the continuation of employment. Restricted share activity is summarized as follows:

	Shares Outstanding			Weighted Average Grant Date Fair Value
Balance at December 31, 2005	—			—
Granted	152,000			5.41
Vested	—			—
Canceled	(13,000	)		5.41
Balance at June 30, 2006	139,000		$	5.41

7

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements-Continued

As of June 30, 2006, there was $507,000 of total unrecognized compensation costs related to the outstanding restricted shares, which is expected to be recognized over a weighted average period of 2.32 years. The Company used a discount factor of 30% to determine the fair value at the date of grant based on an analysis of the Company’s private placement offering completed in March 2004 and other illiquidity factors. The Company estimates the forfeiture rate for restricted stock using 10% for key employees and 15% for non-key employees.

On April 18, 2006, the Company granted stock options to its directors and non-employee medical advisors under the Stock Option Plan. The options issued to the Company’s directors vest over a one-year period based on the continuation of service as a Board member of the Company. The options issued to the Company’s medical advisors vest over a two-year period based on continued service in this capacity to the Company. Stock option activity is summarized as follows:

	Plan Options Outstanding		Exercise Price		Weighted Average Exercise Price
Balance at December 31, 2005	1,715,000		$  0.78— $12.00	$	4.83
Granted	74,000		7.88		7.88
Exercised	(175,000	)	0.78  —    6.74		1.68
Canceled	(52,000	)	0.78  —    9.46		7.52
Balance at June 30, 2006	1,562,000		$0.78—$12.00	$	5.18

As of June 30, 2006, there was $675,000 of total unrecognized compensation costs related to the outstanding stock options, which is expected to be recognized over a weighted average period of 1.00 years.

At June 30, 2006, a total of 1,824,614 shares were available for grant under the Stock Option Plan.

As of June 30, 2006, there was $234,000 of total unrecognized compensation costs related to the employee stock purchase plan, which is expected to be recognized over a weighted average period of 0.86 years.

(3) Net Loss per Share

In accordance with Statement of Financial Accounting Standards No. 128, Earnings Per Share, (SFAS 128), basic net loss per share for the three and six months ended June 30, 2006 and 2005 is computed by dividing net loss by the weighted average common shares outstanding during the periods presented. For all periods presented, diluted loss per share is the same as basic loss per share because the effect of outstanding restricted stock, options and warrants is antidilutive.

8

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements-Continued

Weighted average common shares outstanding for the three and six months ended June 30, 2006 and 2005 was as follows:

	Three Months Ended June 30,		Six Months Ended June 30,
	2006	2005	2006	2005
	(unaudited)		(unaudited)
Weighted average shares outstanding – Basic	14,876,335	14,479,628	14,829,553	14,427,074
Weighted average shares outstanding – diluted	14,876,335	15,599,828	14,829,553	14,427,074

(4) Comprehensive Income (Loss)

Comprehensive income (loss) for the Company includes net income (loss) and foreign currency translation. Comprehensive income (loss) for the three and six months ended June 30, 2006 and 2005 was as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
	2006			2005			2006			2005
	(unaudited)						(unaudited)
Net income (loss)	$	(653,000	)	$	75,000		$	(1,508,000	)	$	(214,000	)
Foreign currency translation adjustments		33,000			(72,000	)		(43,000	)		(129,000	)
Comprehensive income (loss)	$	(620,000	)	$	3,000		$	(1,551,000	)	$	(343,000	)

(5) Revenue Recognition

In the United States and Germany, the Company sells its products directly to hospitals and clinics. Revenue is recognized in accordance with generally accepted accounting principles as outlined in the Securities and Exchange Commission’s Staff Accounting Bulletin No. 104, Revenue Recognition, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectibility is reasonably assured; and (iv) product delivery has occurred or services have been rendered. The Company recognizes revenue as products are shipped based on FOB shipping point terms when title passes to customers. The Company negotiates credit terms on a customer-by-customer basis and products are shipped at an agreed-upon price. All product returns must be pre-approved and, if approved, customers are subject to a 20% restocking charge.

In all other international markets, the Company sells its products to international distributors, which subsequently resell the products to hospitals and clinics. The Company has agreements with each of its distributors which provide that title and risk of loss pass to the distributor upon shipment of the products to the distributor.

9

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements-Continued

The Company warrants that its products are free from manufacturing defects at the time of shipment to the distributor. Revenue is recognized upon shipment of products to distributors following the receipt and acceptance of a distributor’s purchase order. Allowances are provided for estimated returns and warranty costs at the time of shipment.

In accordance with the Emerging Issues Task Force (EITF) issue 00-10, Accounting for Shipping and Handling Fees and Costs, the Company includes shipping and handling revenues in net sales and shipping and handling costs in cost of sales.

(6) Inventories

Inventories are stated at the lower of cost (first-in, first-out method) or market. Appropriate consideration is given to deterioration, obsolescence and other factors in evaluating net realizable value. Inventories are comprised of the following:

	June 30, 2006		December 31, 2005
	(unaudited)
Raw materials	$	5,515,000	$	4,965,000
Work-in process		1,100,000		834,000
Finished goods		1,430,000		1,163,000
	$	8,045,000	$	6,962,000

(7) Credit Risk and Allowance for Doubtful Accounts

The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. This allowance is regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay. Accounts receivable over 60 days past due are considered past due. The Company does not accrue interest on past due accounts receivable. Receivables are written off only after all collection attempts have failed and are based on individual credit evaluation and the specific circumstances of the customer. At June 30, 2006 and December 31, 2005, the allowance for doubtful accounts was $140,000 and $110,000, respectively.

All product returns must be pre-approved and, if approved, customers are subject to a 20% restocking charge. The Company analyzes the rate of historical returns when evaluating the adequacy of the allowance for sales returns, which is included with the allowance for doubtful accounts on our balance sheet. At June 30, 2006 and December 31, 2005, the sales and return allowance was $50,000 and $30,000, respectively.

Accounts receivable are shown net of the combined total of the allowance for doubtful accounts and allowance for sales returns of $190,000 and $140,000 at June 30, 2006 and December 31, 2005, respectively.

10

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements-Continued

(8) Concentrations of Credit and Other Risks

In the United States and Germany, the Company sells its products directly to hospitals and clinics. In all other international markets, the Company sells its products to distributors who, in turn, sell to medical clinics. Loss, termination or ineffectiveness of distributors to effectively promote the Company’s product could have a material adverse effect on the Company’s financial condition and results of operations.

With respect to accounts receivable, the Company performs credit evaluations of its customers and does not require collateral. No single customer represented greater than 5% of gross accounts receivable as of June 30, 2006 and December 31, 2005, respectively. There have been no material losses on customer receivables.

Sales by geographic destination as a percentage of total net sales for both of the six month periods ended June 30, 2006 and 2005 were 88% in the United States, and 12% in international markets. No single customer represented greater than 5% of the total net sales for the six months ended June 30, 2006 and 2005.

(9) Dependence on Key Suppliers

King Pharmaceuticals

The Company purchases certain key components from single-source suppliers. Any significant component delay or interruption could require the Company to qualify new sources of supply, if available, and could have a material adverse effect on the Company’s financial condition and results of operations. The Company purchases its requirements for thrombin (a component in the Duett and D-Stat products) under a Purchase Agreement dated June 10, 1999 with a subsidiary of King Pharmaceuticals, Inc. (King). The agreement provides for the purchase of thrombin at a fixed price, with adjustments based on the supplier’s manufacturing costs and the supplier’s annual percentage increase in the wholesale price of thrombin. The agreement expired on May 29, 2005. In anticipation of the agreement expiring, the Company submitted purchase orders to King for approximately $3.5 million of thrombin to benefit from the pricing provisions of the agreement. The Company expects the final lots of thrombin totaling $1.0 million to be delivered throughout the remainder of 2006. The Company believes that these purchases will satisfy its thrombin requirements through at least the end of 2007.

Sigma

On October 18, 2004, the Company entered into a supply agreement with Sigma-Aldrich Fine Chemicals, an operating division of Sigma-Aldrich, Inc. (Sigma) for the supply of thrombin to the Company. Pursuant to the terms of the agreement, the Company will pay for certain development costs of Sigma to allow Sigma to produce thrombin. The payments are based on achievement of certain milestones over a two-year period. The contract terminates after ten years and is automatically extended for up to five additional successive one-year terms unless one party delivers notice of termination at least one year prior to the scheduled termination of the agreement.

11

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements-Continued

During the term of the contract, Sigma has agreed not to sell thrombin of the type developed for the Company under the contract in or as a component of a hemostatic product for medical use. The Company does not have any minimum purchase requirements under the contract; however, if the Company purchases less than three lots of thrombin in any year then (i) Sigma will be released from its agreement not to sell thrombin in or as a component of a hemostatic product for medical use, and (ii) Sigma will have the right to terminate the contract on 30 days notice.

The Sigma contract was the start of the Company’s plan to fully qualify a new source of thrombin and to bring the new thrombin through the regulatory process to be used in the Company’s hemostatic products starting in 2007. The costs associated with the Sigma agreement are part of the Company’s total estimated expenditures of $7.8 million (including the payments to Sigma) to complete the thrombin qualification project. In the second quarter of 2006, we increased our total estimated expenditures by $1 million due to increased costs associated with our clinical study and the added costs of manufacturing and vialing one additional engineering lot of thrombin. The failure by the Company to complete the thrombin qualification project on time and on budget may affect the Company’s gross margins on the Duett, D-Stat Flowable and D-Stat Dry products and could therefore seriously harm the Company’s business.

The costs and purchases incurred through June 30, 2006 and the total estimated costs and purchases for the thrombin qualification project (including costs and purchases already incurred) are as follows:

	Incurred (as of June 30, 2006)	Total Estimated
Qualification expenses.	$3.5 million	$5.3 million
Capital equipment purchases.	0.8 million	0.8 million
Thrombin inventory purchases.	1.7 million	1.7 million
	$6.0 million	$7.8 million

(10) Contingencies

The description of legal proceedings in Part II, Item 1, Legal Proceedings to this filing is incorporated herein by reference.

(11) Long-term Debt

In 2005, the Company modified and extended the secured asset-based loan and security agreement dated December 31, 2003. In addition to the operating line of credit, the Company added an equipment line of credit. The operating line of credit is a one-year, $5,000,000 facility with availability based primarily on eligible customer receivables and inventory. The interest rate is prime plus 0.5%. As of June 30, 2006, the Company had no outstanding loan balance against the facility.

12

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements-Continued

On January 6, 2006, the Company executed a $2,000,000 advance on the equipment line of credit, discussed above. The advance is secured by various equipment acquired by the Company during the year ended December 31, 2005. The equipment line of credit is a three-year, $2,000,000 facility with an interest rate of prime plus 1.5%.

These lines of credit include two covenants: minimum tangible net worth of $11,000,000 through August 31, 2006, $12,000,000 through November 30, 2006, and $13,000,000 thereafter, and liquidity coverage of not less than 1.25 to 1.00. The Company was in compliance with these covenants at June 30, 2006.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Vascular Solutions, Inc. (we, us or Vascular) is a medical device company focused on bringing clinically advanced solutions to interventional cardiologists and interventional radiologists worldwide. We were incorporated in the state of Minnesota in December 1996, and we began operations in February 1997. Our current product line consists of the following medical devices:

• D-Stat Dry™ hemostatic bandage, a topical pad with a bandage used to control surface bleeding,

• Pronto™ extraction catheter, a mechanical system for the removal of soft thrombus from arteries,

• Vari-Lase® endovenous laser, a laser and procedure kit used for the treatment of varicose veins,

• Duett™ sealing device, used to seal the puncture site following catheterization procedures,

• D-Stat® Flowable hemostat, a thick, yet flowable, mixture used to control bleeding,

• ThrombiGel™ hemostat, a resorbable version of our D-Stat Dry,

• Langston™ dual lumen catheters, used to measure intravascular pressure gradients,

• Twin-Pass™ dual access catheter, used for dual wire access in interventional cardiology procedures,

• Skyway™ exchange catheter, used for guidewire support and exchange in interventional cardiology procedures,

• Access products used to gain percutaneous access to the vasculature,

• MAX-Support™ abdominal retraction belt, used to allow femoral access in obese patients, and

• Acolysis® ultrasound (international only), a treatment for peripheral occlusive arterial disease.

As a vertically-integrated medical device company, we generate ideas and create new interventional medical devices and then deliver these products directly to the physician through our direct domestic sales force and our international distribution network.

We currently have in development several additional products that leverage our existing infrastructure to bring additional solutions to the interventional cardiologist and interventional radiologist. Additional products that we expect to gain regulatory clearance and market launch in the United States within the next twelve months include the following medical devices, each of which we believe addresses an annual market opportunity of between $1 million and $20 million:

• GuideLiner catheter, a specialty-purpose catheter designed to provide back-up support to the guide catheter in difficult coronary procedures,

13

• Gopher catheter, a low profile metal catheter used principally in chronic total occlusion cases to provide improved arterial passage, and

• InnerChange micro-introducer catheter, a series of catheters that combines both a diagnostic catheter and a micro-introducer kit into a single product that will be used principally by interventional radiologists.

Results of Operations

Three and six months ended June 30, 2006 compared to three and six months ended June 30, 2005

Net sales increased 35% to $10,911,000 for the quarter ended June 30, 2006 from $8,079,000 for the quarter ended June 30, 2005. Approximately 87% of our net sales for the quarter ended June 30, 2006 were to customers in the United States and 13% of our net sales were to customers in international markets. Net sales increased 36% to $20,863,000 for the six months ended June 30, 2006 from $15,353,000 for the six months ended June 30, 2005. Approximately 88% of our net sales for the six months ended June 30, 2006 were to customers in the United States and 12% of our net sales were to customers in international markets. Net sales by product category were as follows:

• Net sales of the D-Stat Dry hemostatic bandage were $4,280,000 for the quarter ended June 30, 2006 compared to $3,385,000 in the second quarter of 2005, a 26% increase. Net sales of the D-Stat Dry hemostatic bandage were $8,300,000 for the six months ended June 30, 2006 compared to $6,518,000 in the six month period ended June 30, 2005, a 27% increase.

• Net sales of Pronto extraction catheters were $2,316,000 for the quarter ended June 30, 2006 compared to $1,645,000 in the second quarter of 2005, a 41% increase. Net sales of Pronto extraction catheters were $4,384,000 for the six months ended June 30, 2006 compared to $2,926,000 in the six month period ended June 30, 2005, a 50% increase.

• Net sales of our Vari-Lase product line were $1,648,000 for the quarter ended June 30, 2006 compared to $1,039,000 in the second quarter of 2005, a 59% increase. Net sales of our Vari-Lase product line were $3,098,000 for the six months ended June 30, 2006 compared to $1,833,000 in the six month period ended June 30, 2005, a 69% increase.

• Net sales of our Access product line were $370,000 for the quarter ended June 30, 2006 compared to $145,000 in the second quarter of 2005, a 155% increase. Net sales of our Access product line were $680,000 for the six months ended June 30, 2006 compared to $243,000 in the six month period ended June 30, 2005, a 180% increase.

• Net sales of the D-Stat Flowable hemostat were $671,000 for the quarter ended June 30, 2006 compared to $513,000 in the second quarter of 2005, a 31% increase. Net sales of the D-Stat Flowable hemostat were $1,241,000 for the six months ended June 30, 2006 compared to $974,000 in the six month period ended June 30, 2005, a 27% increase.

• Net sales of our Duett sealing device were $570,000 for the quarter ended June 30, 2006 compared to $1,045,000 in the second quarter of 2005, a 45% decrease. Net sales of our Duett sealing device were $1,263,000 for the six months ended June 30, 2006 compared to $2,303,000 in the six month period ended June 30, 2005, a 45% decrease. We expect Duett sales to continue to decline as we continue to harvest this product and focus on our new higher margin products.

14

• Net sales of our specialty catheters (Langston, Twin-Pass and Skyway) were $846,000 for the quarter ended June 30, 2006 compared to $179,000 in the second quarter of 2005, a 373% increase. Net sales of the specialty catheters were $1,534,000 for the six months ended June 30, 2006 compared to $317,000 in the six month period ended June 30, 2005, a 384% increase. In September 2004 we launched the Langston dual lumen pigtail catheter, in February 2006 we launched the Twin-Pass dual lumen catheter, and in April 2006 we launched the Skyway Exchange Catheter.

• Net sales of our other products were $210,000 for the quarter ended June 30, 2006 compared to $128,000 in the second quarter of 2005, a 64% increase. Net sales of our other products were $363,000 for the six months ended June 30, 2006 compared to $239,000 in the six month period ended June 30, 2005, a 52% increase.

Gross profit as a percentage of net sales decreased to 67% for the quarter ended June 30, 2006 from 71% for the quarter ended June 30, 2005. Gross profit as a percentage of net sales decreased to 67% for the six months June 30, 2006 from 72% for the six months June 30, 2005. We expect gross margins to continue to be in the range of 67% to 70% in 2006 as our selling mix changes. Our new V3 version of the Pronto extraction catheter has higher manufacturing costs than the original Pronto which affected the gross profit in the first six months of 2006. The decrease in margin was also due to the new FAS 123R expense for stock-based compensation.

Research and development expenses increased 6% to $1,026,000 for the quarter ended June 30, 2006 from $965,000 for the quarter ended June 30, 2005. Research and development expenses increased 10% to $2,024,000 for the six months ended June 30, 2006 from $1,844,000 for the six months ended June 30, 2005. The increase was the result of our increased investment in research and development and the new FAS 123R expense for stock-based compensation. We expect our normal research and development expenses to be approximately 10% to 12% of sales per quarter for the remainder of 2006 as we continue to pursue additional new products at an expected rate of approximately two new products per year and as we continue to move our longer-term development projects forward.

Clinical and regulatory expenses increased 15% to $618,000 for the quarter ended June 30, 2006 from $536,000 for the quarter ended June 30, 2005. Clinical and regulatory expenses increased 23% to $1,200,000 for the six months ended June 30, 2006 from $977,000 for the six months ended June 30, 2005. Clinical and regulatory expenses fluctuate due to the timing of clinical and marketing studies. The increase was the result of increased FDA fees, the new FAS 123R expense for stock-based compensation, increased translation services and an increase in the number of employees compared to 2005. We expect clinical and regulatory expenses to be approximately 6% to 8% of sales per quarter in 2006 as we continue to pursue additional new products at an expected rate of approximately two new products per year and as we continue to move our longer-term development projects forward.

Sales and marketing expenses increased 27% to $4,276,000 for the quarter ended June 30, 2006 from $3,380,000 for the quarter ended June 30, 2005. Sales and marketing expenses increased 34% to $8,675,000 for the six months ended June 30, 2006 from $6,470,000 for the six months ended June 30, 2005. The increase in sales and marketing expenses is the direct result of our increase in our direct sales force to 76 employees at June 30, 2006, compared to 68 at June 30, 2005, as well as the new FAS 123R expense for stock-based compensation. We expect to add approximately four more field sales employees during 2006 to complete our geographic coverage of the United States. We expect our sales and marketing expenses to be approximately 38% to 40% of sales per quarter for the remainder of 2006.

15

General and administrative expenses increased 51% to $1,001,000 for the quarter ended June 30, 2006 from $664,000 for the quarter ended June 30, 2005. General and administrative expenses increased 51% to $1,888,000 for the six months ended June 30, 2006 from $1,250,000 for the six months ended June 30, 2005. The increase was principally the result of legal fees and settlement related to the Diomed intellectual property litigation (see “Legal Proceedings” in Item 1 of Part II of this Form 10-Q), along with higher insurance, the new FAS 123R expense for stock-based compensation, and additional headcount. We expect general and administrative expenses to be approximately 8% to 10% of sales per quarter for the remainder of 2006.

Thrombin qualification expenses were $952,000 for the quarter ended June 30, 2006 and $139,000 for the quarter ended June 30, 2005. Thrombin qualification expenses were $1,621,000 for the six months ended June 30, 2006 and $626,000 for the six months ended June 30, 2005. We expect the total remaining expenses associated with our qualification of the new source of thrombin to be approximately $1.8 million, with the majority of these expenses to be incurred in 2006.

Amortization of purchased technology was $18,000 for the quarter ended June 30, 2006 and $54,000 for the quarter ended June 30, 2005. Amortization of purchased technology was $73,000 for the six months ended June 30, 2006 and $109,000 for the six months ended June 30, 2005. The amortization resulted from our acquisition of the Acolysis assets from the secured creditors of Angiosonics, Inc. in 2002. We allocated $870,000 of the acquisition price to purchased technology and amortized the amount over four years. In the second quarter of 2006 we completed the amortization of the purchased technology and will not incur additional amortization expense charges for the remainder of 2006.

Interest expense increased to $54,000 for the quarter ended June 30, 2006 from $0 for the quarter ended June 30, 2005. Interest expense increased to $102,000 for the six months ended June 30, 2006 from $0 for the six months ended June 30, 2005. Interest expense is a result of the borrowings on an equipment line of credit in January 2006.

Interest income decreased to $28,000 for the quarter ended June 30, 2006 from $42,000 for the quarter ended June 30, 2005. Interest income decreased to $59,000 for the six months ended June 30, 2006 from $75,000 for the six months ended June 30, 2005. The decline in interest income is directly attributable to the decreased cash balance.

Income Taxes

We have not generated any fiscal year pre-tax income to date and therefore have not paid any federal income taxes since our inception in December 1996. No provision or benefit for federal and state income taxes has been recorded for net operating losses incurred in any period since our inception.

As of June 30, 2006, we had approximately $58.4 million of federal net operating loss carryforwards available to offset future taxable income which begin to expire in the year 2013. As of June 30, 2006, we also had federal and state research and development tax credit carryforwards of approximately $2.4 million which begin to expire in the year 2013. As of June 30, 2006, we also had a foreign tax loss carryforward of approximately $2.5 million, which does not expire. Under the United States Tax Reform Act of 1986, the amounts of and benefits from net operating loss carryforwards may be impaired or limited in certain circumstances, including significant changes in ownership interests. Future use of our existing net operating loss carryforwards may be restricted due to changes in ownership or from future tax legislation. We performed a section 382 “change in ownership” study during the third quarter 2005 on our federal net operating loss carryforward, and we concluded that we will have no limitations on the net operating loss carryforward.

16

Liquidity and Capital Resources

We have financed all of our operations since inception through the issuance of equity securities, $2,000,000 in borrowings under an equipment line of credit and sales of our products. Through June 30, 2006, we had sold capital stock generating aggregate net proceeds of approximately $79 million. At June 30, 2006, we had $2,226,000 in cash and cash equivalents on-hand compared to $4,282,000 at December 31, 2005.

During the six months ended June 30, 2006, we used $3,902,000 in cash as a result of operating activities, we incurred capital expenditures in the amount of $797,000, and we generated $2,580,000 in financing activities. Our operating cash usage was primarily the result of our planned build-up of thrombin from our current supplier, approximately $1.2 million of cash used, as well as for expenditures to further our qualification of our new source of thrombin, approximately $1.4 million of cash used. The majority of the capital expenditures were for leasehold improvements and upgraded manufacturing equipment. Approximately $580,000 of the cash provided by financing activities was through the sale of common stock upon the exercise of outstanding stock options, stock warrants and the employee stock purchase plan. The remaining $2,000,000 of financing proceeds was the result of our draw on our line of credit in January 2006.

We purchase our requirements for thrombin (a component in the Duett and in all of the D-Stat products) under a Purchase Agreement dated June 10, 1999 with a subsidiary of King. The agreement provides for a fixed price, with adjustments based on the supplier’s manufacturing costs and the supplier’s annual percentage increase in the wholesale price of thrombin. The agreement expired on May 29, 2005. Prior to the expiration of the agreement, we issued purchase orders for approximately $3.5 million of thrombin to benefit from the pricing provisions of the agreement, which thrombin we expect to be delivered through the third quarter of 2006. We believe that these purchases will satisfy our thrombin requirements through at least the end of 2007. We have taken delivery of approximately $2.5 million of the $3.5 million of King thrombin through June 30, 2006. We have executed a supply agreement for a new source of thrombin, which we plan to fully qualify and bring through the regulatory process by the second quarter of 2007 at a cumulative cost of approximately $5.3 million in development and qualification expenditures, of which approximately $1.8 million of the expenses remain and the majority of these expenses are projected to be incurred in 2006. We have purchased $800,000 in capital expenditures out of our total planned capital expenditures of $800,000. We also purchased $1.7 million of thrombin from our new supplier prior to the end of 2005, which fulfilled our thrombin purchase requirement. With the thrombin already purchased and our planned additional King thrombin purchases, we expect our inventory to peak at approximately $9 million at the end of the fourth quarter of 2006, and then decrease throughout 2007 as the King thrombin is used in our products. This investment, while substantial, is within our projected capital resources and we expect will allow us to introduce new thrombin-based products as well as control our long-term cost of thrombin. The failure by us to complete our thrombin qualification project on time and on budget may affect our gross margins on our Duett, D-Stat Flowable and D-Stat Dry products and could therefore seriously harm our business.

We currently have a $7 million credit facility with Silicon Valley Bank. Of this facility, the $5 million revolving line of credit has a 12-month term, bears interest at the rate of prime plus 0.5% and is secured by a first security interest on all of our assets. The $2 million equipment line of credit has a 36-month term, bears interest at the rate of prime plus 1.5% and is secured by a first security interest on all of our assets. The credit facility includes two covenants: minimum tangible net worth of $11,000,000 through August 31, 2006, $12,000,000 through November 30, 2006, and $13,000,000 thereafter, and liquidity coverage of not less than 1.25 to 1.00. We were in compliance with the financial covenants at June 30, 2006. On January 6, 2006, we drew down $2 million of the equipment line. As of June 30, 2006, we had a $2,000,000 outstanding balance on the $7 million credit facility and the availability of the $5 million revolving line of credit was $5 million.

17

The following table summarizes our contractual cash commitments as of June 30, 2006:

	Payments Due by Period
Contractual Obligations	Total		Less than 1 year		1-3 years		3-5 years		More then 5 years
Facility Operating Leases	$	774,000	$	344,000	$	430,000	$	—	$	—
Long-term debt		2,000,000		733,000		1,267,000		—		—
Sigma Contract Commitment		200,000		200,000		—		—		—
King Pharmaceutical Thrombin Purchases		1,003,000		1,003,000		—		—		—
Total Contractual Cash Obligations	$	3,977,000	$	2,280,000	$	1,697,000	$	—	$	—

We do not have any other significant cash commitments related to supply agreements, nor do we have any significant commitments for capital expenditures.

We currently anticipate that we will continue to experience positive cash flow from our normal operating activities, excluding requirements associated with our new supply of thrombin. We currently believe that our working capital of $11.6 million at June 30, 2006, our $5 million line of credit and our anticipated cash from product sales will be sufficient to meet all of our operating and capital requirements, including our thrombin inventory purchases under our current thrombin supply contract and our costs associated with the new supply of thrombin. However, our actual liquidity and capital requirements will depend upon numerous factors, including the costs and timing of expansion of sales and marketing activities; the amount of revenues from sales of our existing and new products; the cost of maintaining, enforcing and defending patents and other intellectual property rights; competing technological and market developments; developments related to regulatory and third party reimbursement matters; the cost and progress of our research and development efforts; and other factors.

If cash generated from operations is insufficient to satisfy our cash needs, we may be required to raise additional funds. In the event that additional financing is needed, and depending on market conditions, we may seek to raise additional funds for working capital purposes through the sale of equity or debt securities.

Critical Accounting Policies

Management’s Discussion and Analysis of Financial Condition and Results of Operations addresses our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. The preparation of our financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate these estimates and judgments. We base our estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We set forth below those material accounting policies that we believe are the most critical to an investor’s understanding of our financial results and condition and which require complex management judgment.

18

Inventory

We state our inventory at the lower of cost (first-in, first-out method) or market. The estimated value of excess, obsolete and slow-moving inventory as well as inventory with a carrying value in excess of its net realizable value is established by us on a quarterly basis through review of inventory on hand and assessment of future demand, anticipated release of new products into the market, historical experience and product expiration. Our stated value of inventory could be materially different if demand for our products decreased because of competitive conditions or market acceptance, or if products become obsolete because of advancements in the industry.

Revenue Recognition

We recognize revenue in accordance with generally accepted accounting principles as outlined in the Securities and Exchange Commission’s Staff Accounting Bulletin No. 104 Revenue Recognition, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectibility is reasonably assured; and (iv) product delivery has occurred or services have been rendered. We recognize revenue as products are shipped based on FOB shipping point terms when title passes to customers. We negotiate credit terms on a customer-by-customer basis and products are shipped at an agreed upon price. All product returns must be pre-approved and, if approved, customers are subject to a 20% restocking charge.

We analyze the rate of historical returns when evaluating the adequacy of the allowance for sales returns, which is included with the allowance for doubtful accounts on our balance sheet. At June 30, 2006, this reserve was $50,000 compared to $30,000 at December 31, 2005. If the historical data we use to calculate these estimates does not properly reflect future returns, revenue could be overstated.

Allowance for Doubtful Accounts

We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. This allowance is regularly evaluated by us for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay. At June 30, 2006, this reserve was $140,000 compared to $110,000 at December 31, 2005. If the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.

Warranty Costs

We provide a warranty for certain products against defects in material and workmanship for periods of up to 24 months. We record a liability for warranty claims at the time of sale. The amount of the liability is based on the amount we are charged by our original equipment manufacturer to cover the warranty period. The original equipment manufacturer includes a year warranty with each product sold to us. We record a liability for the uncovered warranty period offered to a customer, provided the warranty period offered exceeds the initial one-year warranty period covered by the original equipment manufacturer. At June 30, 2006 and December 31, 2005, this warranty provision was $50,000. If the assumptions used in calculating the provision were to materially change, resulting in more defects than anticipated, an additional provision may be required.

19

Income Taxes

The carrying value of our net deferred tax assets assumes that we will be able to generate sufficient taxable income in the United States and, to a lesser extent, Germany, based on estimates and assumptions. We record a valuation allowance to reduce the carrying value of our net deferred tax asset to the amount that is more likely than not to be realized. At June 30, 2006, we recorded a $27.0 million valuation allowance related to our net deferred tax assets of $27.0 million. In the event we were to determine that we would be able to realize our deferred tax assets in the future, an adjustment to the deferred tax asset would increase net income in the period such determination is made. On a quarterly basis, we evaluate the realizability of our deferred tax assets and assess the requirement for a valuation allowance.

Stock-Based Compensation

We account for stock-based compensation in accordance with SFAS No. 123(R), Share-Based Payment. Under the fair value recognition provisions of this statement, share-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. Determining the fair value of share-based awards at the grant date requires judgment, including estimating expected dividends, estimating expected forfeiture rates, estimating expected stock volatility, estimating the expected term, estimating expected risk-free interest rates and determining illiquidity discount rates. If actual results differ significantly from these estimates and we materially change our estimates, stock-based compensation expense and our results of operations could be materially impacted.

Cautionary Statement Pursuant to the Private Securities Litigation Reform Act of 1995

The Private Securities Litigation Reform Act of 1995 (the Act) provides a “safe harbor” for forward-looking statements to encourage companies to provide prospective information about their business, so long as those statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those discussed in the statement. We desire to take advantage of the safe harbor provisions with respect to any forward-looking statements we may make in this filing, other filings with the Securities and Exchange Commission and any public oral statements or written releases. The words or phrases “will likely,” “is expected,” “will continue,” “is anticipated,” “believes”, “estimate,” “projected,” “forecast,” or similar expressions are intended to identify forward-looking statements within the meaning of the Act. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. In accordance with the Act, we identify the following important general factors which, if altered from the current status, could cause our actual results to differ from those described in any forward-looking statements: risks associated with our limited operating history, the qualification of a new source of thrombin, defense of patent infringement lawsuits, adoption of our new products, lack of profitability, lack of experience with a direct sales force, exposure to possible product liability claims, the development of new products by others, dependence on third party distributors in international markets, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, actions by the Food and Drug Administration (FDA) related to our products, the loss of key vendors, and those factors set forth under the heading “Risk Factors” in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2005. This list is not exhaustive, and we may supplement this list in any future filing with the Securities and Exchange Commission or in connection with the making of any specific forward-looking statement.

20

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivables. We maintain our accounts for cash and cash equivalents principally at one major bank and one investment firm in the United States. We have a formal written investment policy that restricts the placement of investments to issuers evaluated as creditworthy. We have not experienced any losses on our deposits of our cash and cash equivalents.

With respect to accounts receivable, we perform credit evaluations of our customers and do not require collateral. There have been no material losses on accounts receivables.

In the United States and Germany, we sell our products directly to hospitals and clinics in the local currency.

In all other international markets, we sell our products to independent distributors who, in turn, sell to medical clinics. We sell our product in these countries through independent distributors denominated in United States dollars. Loss, termination or ineffectiveness of distributors to effectively promote our product would have a material adverse effect on our financial condition and results of operations.

We do not believe our operations are currently subject to significant market risks for interest rates, foreign currency exchange rates, commodity prices or other relevant market price risks of a material nature.

We currently have borrowed $2,000,000 from our equipment line. We are exposed to changes in interest rates as our current equipment advance and future advances under our revolving line of credit bear interest at an annual rate indexed to prime. We are thus exposed to interest rate risk with respect to these lines of credit to the extent that interest rates rise when there are amounts outstanding under these lines of credit. Based on our debt outstanding at June 30, 2006, a 1% increase in current market interest rates would have an impact of approximately $20,000 on an annual basis. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the Exchange Act)). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective.

Changes in internal controls.

During the fiscal quarter ended June 30, 2006, there has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

21

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

On December 11, 2003, we and one of our non-officer former employees were named as defendants in a lawsuit brought by Diomed Holdings, Inc. (Diomed), in the United States District Court for the District of Massachusetts. The complaint alleged that in marketing our Vari-Lase endovenous laser procedure kit we engaged in false advertising and infringed a registered trademark of Diomed. The complaint also alleged that the non-officer former employee, who previously worked for a company that conducted business with Diomed, improperly utilized trade secrets of Diomed in developing our Vari-Lase procedure kit. The complaint requested monetary damages and an injunction on the sale of our Vari-Lase procedure kit. On January 31, 2006, the Court granted our motion for summary judgment dismissing all counts of Diomed’s complaint with the exception of one trade secret misappropriation count and a portion of two other counts to the extent they are based on alleged trade secret misappropriation. Our counterclaim against Diomed was not dismissed. On June 23, 2006, we entered into an agreement with Diomed that settled the litigation and all issues surrounding Diomed’s marked sheath patents. The terms of the settlement are confidential. The settlement did not affect the ongoing dispute between the parties regarding Diomed’s United States Patent Number 6,398,777 discussed below.

On March 4, 2004, we were named as the defendant in an intellectual property lawsuit brought by Diomed in the United States District Court for the District of Massachusetts.  The complaint requested a judgment that our Vari-Lase procedure kit and Vari-Lase laser console infringe on a single patent (No. 6,398,777) held by Diomed, Inc. and asked for relief in the form of an injunction that would prevent us from selling our Vari-Lase products, compensatory and treble damages caused by the manufacture and sale of our product, and other costs, disbursements and attorneys’ fees. On April 12, 2005, the judge entered a Memorandum and Order on Claims Construction from the Markman hearing phase of the litigation. In the Order, the judge held that in order to violate the Diomed patent, a competing method must deliberately put the tip of the laser fiber in physical contact with the wall of the vein, must drain blood from the vein, must compress the vein and must maintain vein wall contact as the laser energy is delivered. We believe that our Vari-Lase products are not used in this method, and thus we do not believe the litigation has merit. On December 21, 2005, we filed our motion for summary judgment, in which we seek dismissal of all claims, and Diomed filed its motion for summary judgment, in which it seeks a judgment of validity and infringement. Oral arguments on the summary judgment motions were scheduled to occur on June 1, 2006. That hearing was postponed by the court while all parties responded to an order of the court dated May 22, 2006, wherein the judge indicated he had recently been referred to and consulted with a physician concerning a proposed laser treatment. The consulting physician has been engaged by Diomed as an expert witness in the case. On June 22, 2006, the judge issued an Order of Recusal, and a new judge has been assigned to this case. It is not possible to predict the timing or outcome of this litigation, including whether it will affect our ability to sell our Vari-Lase products, or to estimate the amount or range of potential loss.

On October 13, 2005, we were named as one of three defendants in an intellectual property lawsuit brought by VNUS Medical Technologies, Inc. in the United States District Court for the Northern District of California. The complaint requested a judgment that our Vari-Lase procedure kit and Vari-Lase laser console infringes on four patents held by VNUS Medical Technologies, Inc. and asked for relief in the form of an injunction that would prevent us from selling our Vari-Lase products, compensatory and treble damages caused by the manufacture and sale of our product, and other costs, disbursements and attorneys’ fees. We believe that our Vari-Lase products do not violate these patents, and thus we do not believe the litigation has merit. It is not possible to predict the timing or outcome of this litigation, including whether it will affect our ability to sell our Vari-Lase products, or to estimate the amount or range of potential loss.

22

From time to time we are involved in legal proceedings arising in the normal course of our business. As of the date of this report we are not a party to any legal proceeding not described in this section in which an adverse outcome would reasonably be expected to have a material adverse effect on our results of operations or financial condition.

Item 1A. Risk Factors

We do not have material changes to our risk factors set forth under Item 1A of Part I of our most recently filed Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Submission of Matters to a Vote of Security Holders

The information contained in Item 4 of Part II of our Form 10-Q for the quarter ended March 31, 2006 is incorporated herein by reference.

Item 5. Other Information

None.

23

Item 6.Exhibits

Exhibit Number	Description
3.1	Amended and Restated Articles of Incorporation of Vascular Solutions, Inc. (incorporated by reference to Exhibit 3.1 to Vascular Solutions’ Form 10-Q for the quarter ended September 30, 2000).
3.2	Bylaws of Vascular Solutions, Inc. (incorporated by reference to Exhibit 3.2 of Vascular Solutions’ Registration Statement on Form S-1 (File No. 333-84089)).
4.1	Specimen of Common Stock certificate (incorporated by reference to Exhibit 4.1 of Vascular Solutions’ Registration Statement on Form S-1 (File No. 333-84089)).
4.2	Form of warrant dated January 31 and February 14, 1997 issued to representatives of Miller, Johnson & Kuehn, Incorporated (incorporated by reference to Exhibit 4.2 of Vascular Solutions’ Registration Statement on Form S-1 (File No. 333-84089)).
4.3	Form of warrant dated December 29, 1997 issued to representatives of Miller, Johnson & Kuehn, Incorporated (incorporated by reference to Exhibit 4.3 of Vascular Solutions’ Registration Statement on Form S-1 (File No. 333-84089)).
4.4	Amended and Restated Investors’ Rights Agreement dated December 9, 1998, by and between Vascular Solutions, Inc. and the purchasers of Series A and Series B preferred stock (incorporated by reference to Exhibit 4.4 of Vascular Solutions’ Registration Statement on Form S-1 (File No. 333-84089)).
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

24

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		VASCULAR SOLUTIONS, INC.
Date:	July 26, 2006	By:	/s/ Howard Root
			Howard Root
			Chief Executive Officer and Director
			(principal executive officer and duly authorized officer)
		By:	/s/ James Hennen
			James Hennen
			Chief Financial Officer
			(principal financial officer)
		By:	/s/ Timothy Slayton
			Timothy Slayton
			Controller
			(principal accounting officer

25